PRESS RELEASE published on 03/14/2024 at 09:00, 6 months 5 days ago Amolyt Pharma, an Andera Partners’ portfolio company, announces its sale to AstraZeneca Amolyt Pharma, a clinical-stage biopharmaceutical company specializing in therapeutic peptides, is being acquired by AstraZeneca for $1.05 billion. The transaction is expected to close in Q3 2024 Acquisition AstraZeneca Amolyt Pharma Therapeutic Peptides Rare Endocrine Diseases
PRESS RELEASE published on 05/15/2023 at 09:00, 1 year 4 months ago Andera Partners co-leads a €40 million Series A of Dualyx, a Belgian biotech developing novel Treg therapies for autoimmune diseases
PRESS RELEASE published on 05/10/2023 at 09:00, 1 year 4 months ago Andera Partners appoints Stefan Keitel Senior Advisor DACH region further strengthening its presence in the German, Austrian and Swiss private equity markets
PRESS RELEASE published on 04/18/2023 at 09:15, 1 year 5 months ago Andera Partners co-leads a Series A extension round totalling € 47.75 million for radiopharmaceutical company Ariceum Therapeutics
PRESS RELEASE published on 04/13/2023 at 12:45, 1 year 5 months ago Andera Partners leads $48.5 Million Series A financing for medical device company BioVentrix®
PRESS RELEASE published on 03/15/2023 at 13:05, 1 year 6 months ago Andera Partners co-leads $25m extension round for FIRE1, an Irish medtech developing breakthrough technology for patients with heart failure
PRESS RELEASE published on 02/16/2023 at 09:00, 1 year 7 months ago Ahead of its business plan, Andera Partners approaches 4 billion euros in assets under management and announces a new 2028 target of 6 to 8 billion euros
PRESS RELEASE published on 02/14/2023 at 09:00, 1 year 7 months ago Andera Partners Portfolio Company Mineralys Therapeutics Successfully Completes Upsized $192 Million Nasdaq IPO
PRESS RELEASE published on 01/26/2023 at 13:10, 1 year 7 months ago Andera Partners Participates in the €45 Million Series B Financing of Grey Wolf Therapeutics, led by Pfizer Ventures, to Advance First-of-its-Kind Neoantigen Creation Approaches
PRESS RELEASE published on 01/10/2023 at 08:30, 1 year 8 months ago Andera Partners invests in SoniVie, a medtech company developing a promising device for the treatment of hypertension
Published on 09/19/2024 at 23:15, 16 minutes ago Cypher Metaverse Inc. Announces Second Closing of Financing
Published on 09/19/2024 at 23:00, 31 minutes ago WestJet Partners with FLYHT and NOAA to Improve Weather Forecasting in North America
Published on 09/19/2024 at 20:15, 3 hours 16 minutes ago Living Security Named a Leader in Human Risk Management, Closely Watched Tech Industry Report
Published on 09/19/2024 at 21:09, 2 hours 21 minutes ago EQS-Adhoc: Mercedes-Benz Group AG adjusts full-year guidance for the year 2024 based on current market outlook
Published on 09/19/2024 at 18:44, 4 hours 46 minutes ago Fuller, Smith & Turner PLC: Transaction in own shares
Published on 09/19/2024 at 18:03, 5 hours 27 minutes ago Funding Circle Plc: POS-Transaction in Own Shares
Published on 09/19/2024 at 17:52, 5 hours 38 minutes ago PILOT 28 : FIGEAC AÉRO remporte 3 nouveaux contrats sur l'A320 pour 65 millions d'euros
Published on 09/19/2024 at 17:52, 5 hours 38 minutes ago PILOT 28: FIGEAC AÉRO secures 3 new wins on the A320 airframe for 65 million euros
Published on 09/19/2024 at 17:45, 5 hours 46 minutes ago Gimv draagt helft van participatie in Infravest over aan WorxInvest (communicatie in toepassing van artikel 7:97 WVV)
Published on 09/19/2024 at 17:45, 5 hours 46 minutes ago Gimv sells half of participation in Infravest to WorxInvest (communication pursuant to article 7:97 BCAC)
Published on 09/19/2024 at 17:45, 5 hours 46 minutes ago Gimv sells half of participation in Infravest to WorxInvest (communication pursuant to article 7:97 BCAC)